Leonard Braden Michael's Form 4 filing
Aclaris Therapeutics, Inc. (ACRS) · filed Jul 1, 2024
- Accession no.
- 0001373604-24-000042
- Filed
- Jul 1, 2024
- Trade date
- Jun 27-Jul 1, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $1.74M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Braden MichaelCIK 0001373603 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 27, 2024 | Common Stock | PPurchaseAcquired | +235,000 | $1.15F2 | +$270,250 | 11,787,134 | Indirect | |
| Jun 28, 2024 | Common Stock | PPurchaseAcquired | +801,000 | $1.12F3 | +$897,120 | 12,588,134 | Indirect | |
| Jun 28, 2024 | Common Stock | PPurchaseAcquired | +400,000 | $1.13 | +$452,000 | 12,988,134 | Indirect | |
| Jul 1, 2024 | Common Stock | PPurchaseAcquired | +107,434 | $1.14F4 | +$122,474.76 | 13,095,572 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1546 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F3
Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1193 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1373per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.